While Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY) still rule the weight-loss drug market with their respective GLP-1 medications, competition could soon be heating up as rival products near ...

GLP-1 medications have become popular for weight loss, and for good reason—they can help regulate appetite and support weight ...

Jim Cramer, the host of Mad Money, discussed the upcoming market and corporate activity to look forward to this week, which ...

Helix, a leader in precision health, is unveiling a new comprehensive clinico-genomic dataset of over 15,000 patients treated with glucagon-like-peptide-1 (GLP-1) agonists including semaglutide, ...

An hour of moderate-intensity exercise reduced sensations of hunger in people with overweight and obesity in a recent study.

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

Telehealth company Hims & Hers' first Super Bowl ad is provocative and effective in building awareness of its weight loss ...

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

Beta-glucan in oats and barley may help with weight loss by controlling blood sugar and reducing fat.

Studies have suggested that GLP-1RAs may show promise for a host of conditions, from alcohol use disorder to Parkinson’s. But ...

Research tells us that eating enough protein and staying physically active can be helpful in reducing the amount of non-fat ...

Research on the gut microbiome has triggered a 'revolution' in nutritional science, and in the last few years, dietary fiber ...